PCSK9 and atherosclerosis: Taken together, there is strong genetic, epidemiological, and clinical proof-of-concept data that targeting PCSK9 significantly reduces plasma LDL-C levels and lowers the risk of ASCVD at least for the mAbs, as discussed above.